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Abstract
Importance—Tumor-infiltrating lymphocytes at diagnosis are reported to be prognostic in triple-
negative breast cancer.
Objective—Here we evaluate the association of stromal tumor infiltrating lymphocytes (STILs) 
with recurrence-free survival (RFS) in N9831 HER2-positive patients treated with chemotherapy 
or chemotherapy plus trastuzumab.
Design—H&E tumor slides from patients on N9831 Arm A (standard AC→T chemotherapy) 
and Arm C (concurrent chemotherapy with trastuzumab) were assessed for STILs. STILs were 
quantitated in deciles and ≥60% STILs was used for the pre-specified categorical cutoff. The 
association between STILs and recurrence-free survival (RFS) was evaluated with Cox models.
Setting—Academic medical center
Participants—Tumor specimens from patients with early stage HER2+ breast cancer.
Intervention(s) for clinical trials or exposure(s) for observational studies—None.
Main outcome measures—Stromal tumor infiltrating lymphocytes (STILs) and their 
association with relapse-free survival.
Results—489 pts from Arm A and 456 pts from Arm C were assessed with a median follow-up 
of 4.4 years. The 10 year Kaplan-Meier estimates for RFS in Arm A were 90.9% and 64.5% for 
patients with high STILs and low STILs, respectively (HR 0.23; 95%CI: 0.073 to 0.73; p=0.013). 
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The 10 year estimates for RFS in Arm C were 80.0% and 80.1% for patients with high STILs and 
low STILs, respectively (HR 1.26; 95%CI: 0.5 to 3.2; p=0.63). The test for interaction between 
trastuzumab treatment and STILS status was statistically significant (p=0.026). In a multivariable 
analysis, STILs status remained significantly associated with RFS in Arm A and not significantly 
associated in Arm C (interaction p=0.042).
Conclusions and relevance—The analysis of N9831 patients found that STILs were 
prognostically associated with RFS in patients treated with chemotherapy alone, but not 
prognostically associated with RFS in patients treated with chemotherapy plus trastuzumab. High 
STILS were predictive of lack of trastuzumab benefit in contrast to a previously reported 
association between increased STILs and increased trastuzumab benefit in HER2 positive patients.
Trial Registration—Trial registration information: Clinicaltrials.gov, NCT00005970, https://
clinicaltrials.gov/show/NCT00005970
INTRODUCTION
The presence of dense lymphocytic infiltrates in breast carcinoma has long been recognized 
by breast histopathologists.1 The term medullary carcinoma was first employed back in 
1949 to describe a high grade breast carcinoma growing in anastomosing sheets comprised 
of large cells with numerous mitoses and an “intimate” stromal lymphoid infiltrate that was 
associated with a better than average prognosis.”1 The association of dense stromal 
lymphocytic infiltrates characteristic of medullary carcinoma and a good prognosis 
continued to be documented though-out the twentieth century; however, the etiology of this 
better prognosis remained uncertain.2–4 Medullary carcinomas are by definition estrogen 
receptor negative. Microarray-based comparative genomic hybridization studies examining 
the enriched tumor DNA of medullary carcinoma show that medullary breast carcinomas 
share common genomic alterations with basal-like carcinomas, the most frequent being 1q 
and 8q gains and X losses. However, medullary breast carcinomas appear to be a distinct 
entity within the basal-like spectrum characterized by a higher proportions of genome copy 
number aberrations than basal carcinomas and recurrent 10p, 9p and 16q gains, 4p losses, 
and 1q, 8p, 10p and 12p amplicons and most importantly are associated with “better 
prognosis”.5,6
Today, the role of the immune system in breast cancer development and outcome is 
undergoing significant study, especially in the setting of triple negative (TNBC) and human 
epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent retrospective 
analyses have demonstrated a prognostic association of stromal tumor infiltrating 
lymphocytes (STILs) with outcome in patients receiving adjuvant or neoadjuvant 
chemotherapy for triple negative breast cancer7–13. These studies have confirmed that TILs 
are most frequently found in highly proliferative TNBC and to a slightly lesser degree 
HER2–positive breast cancer. Their presence at diagnosis is associated with pathologic 
response to neoadjuvant therapy, disease-free (DFS) and overall survival (OS) after adjuvant 
chemotherapy8–10,14,15. Subset analysis of HER2-positive breast cancers from the BIG 
02-98 adjuvant study has documented higher levels of TILs were significantly associated 
with improved survival in patients who did not receive taxane10. Furthermore, analysis of 
HER2+ cancers from patients enrolled in FinHER adjuvant study has suggested that STILs 
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are predictive of benefit to adjuvant trastuzumab14. However, these data from FinHER trial 
are based on only 209 patients randomized to chemotherapy +/− trastuzumab and associated 
with small number of events (N=49 events) between the two treatment groups. The goal of 
the current study was to determine whether the data from FinHER could be validated in a 
larger adjuvant trial with the standard 1 year of trastuzumab such as N9831.
Herein we describe a prospective-retrospective exploratory analysis of STILs and 
recurrence-free survival (RFS) outcome in patients enrolled in the N9831 adjuvant trial 
which evaluated chemotherapy alone or chemotherapy with trastuzumab in patients with 
early stage HER2-positive breast cancer. Guidelines followed for our analysis included 
those recommended by Simon et al16 and the REMARK (Reporting Recommendations for 
Tumor Marker Prognostic Studies)17. Archived specimens collected at baseline for patients 
with centrally tested HER2-positive breast cancer enrolled in Arms A and C of N9831 
(chemotherapy alone, Arm A vs. chemotherapy plus concurrent trastuzumab, Arm C) were 
evaluated. Arm C represents the current standard of care, and this arm exhibited maximum 
difference in RFS after trastuzumab, compared to RFS after chemotherapy alone (Arm A 10 
year RFS =67.1%; Arm C 10 year RFS =79.7%)18. The purpose of our analyses was to 
determine whether STILs is predictive of RFS for HER2+ patients treated with trastuzumab.
PATIENTS AND METHODS
Study Patients
The N9831 Phase III randomized trial included 3505 women with histologically confirmed 
node-positive or high-risk node-negative HER2-positive invasive breast cancer. Eligible 
patients were randomly assigned to doxorubicin and cyclophosphamide (doxorubicin/
cyclophosphamide or AC) followed by weekly paclitaxel (control arm, Arm A); AC 
followed by weekly paclitaxel followed by trastuzumab (sequential arm, Arm B); or AC 
followed by weekly paclitaxel plus trastuzumab followed by trastuzumab alone (concurrent 
arm, Arm C). Results of the different arms of N9831 were published in 2011, demonstrating 
that although each trastuzumab-containing arm led to statistically significant better disease-
free survival compared to chemotherapy alone, the largest difference was observed in the 
Arm C versus Arm A comparisons. The present analyses included only patients randomly 
assigned to Arms A or C, enrolled from May 25, 2000 through April 25, 2005. Radiation 
and/or hormonal therapy were administered after the completion of chemotherapy, as 
indicated. Patient accrual occurred from 2000–2005; follow-up is ongoing although the 
primary and secondary clinical objectives have been published18,19. Baseline ER, PR, and 
HER2+ status was assessed according to protocol guidelines as described previously18.
Pathologic Analysis of STILs
Histopathologic analysis of the percentage of STILs was prespecified and performed using a 
single H&E (hematoxylin and eosin) stained section from each tumor using the criteria by 
Loi et al, Denkert et al, and Adams et al9–11,20. STILs were defined as the percentage of 
tumor stroma containing infiltrating lymphocytes that were not in direct contact with tumor 
cells from an assessment of the entire tumor containing area of the section. Areas of non-
invasive cancer or crush artifacts were not included in the analyses. The STIL data were 
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collected as deciles. Specifically, each specimen was determined to consist of 0–9%, 10–
19%, 20–29%, 30–29%, 40–49%, 50–59%, 60–69%, 70–79%, 80–89%, or 90–100% STILs. 
A priori, tumors were classified as lymphocyte predominant breast cancer (LPBC) if they 
consisted of ≥ 60% STILs consistent with Denkert et al15. This histopathological review was 
conducted in tandem by two pathologists for the first 100 cases (F.L.B., H.B.) followed by a 
single pathologist (H.B.). 12 samples were randomly selected from each of the 10 STIL bins 
(N=120) and an independent pathologist (S.B.) reviewed them using the same published 
criteria but without any teaching set15,20. All were blinded to the patient’s treatment 
assignment, tumor staging, and clinical outcome.
Statistical Analyses
Differences in continuous variables between groups were evaluated with a t-test or a 
Wilcoxon rank sum test if the distribution was skewed. Differences in categorical variables 
were evaluated with a chi-square test. The inter-rater agreement was assessed with a 
weighted Kappa statistic where 0 indicates no agreement and 1 indicates perfect agreement. 
Recurrence-free survival was defined as time from randomization until recurrent disease 
(local, regional, or distant recurrence of breast cancer). Patients who had not experienced a 
disease recurrence at the time of last follow-up or death were censored at the date of last 
follow-up or death. Kaplan-Meier curves were used to summarize the RFS experience and 
the curves were compared with a log-rank test. A Cox proportional model was used to 
determine whether there was an interaction between LPBC status and treatment arm in terms 
of an association with RFS. The model contained the main effects (treatment arm and LPBC 
status) as well as the interaction term of LPBC status*treatment arm. Since the interaction 
term was significant, separate analyses were done for each treatment arm. Univariable and 
multivariable Cox models were used to generate hazard ratios and corresponding 95% 
confidence intervals (CIs) for determining associations between variables of interest and 
RFS. A secondary analysis was performed using the decile levels as continuous 
measurements in place of LPBC status within the Cox models; the coding of the deciles was 
0–9% coded as 1, 10%–19% coded as 2, 20–29% as 3, etcetera. This recoded variable was 
treated as continuous.
This was an unplanned ad hoc analysis with a pre-determine sample size that resulted from 
the number of patients enrolled in the trial who had consented to the use of their specimen 
for analysis and who sufficient tumor tissue for analysis. Given the sample size for this 
analysis was pre-determined by the number of patients who were consented and who had 
materials for correlative sciences, a power calculation was not done. Instead, we provide 
95% CIs for all the results so that the reader can decided whether the intervals contain 
values that would be considered clinically significant in the cases where the results were not 
found to be significant.
RESULTS
Patient characteristics
There was a total of 2027 eligible patients enrolled on Arms A and C of N9831: 1081 on 
Arm A and 946 on Arm C. A subset of 945 patients was included in the STILs analysis. 
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These patients were eligible and had provided sufficient tissue for analysis (see Figure 1). A 
comparison between those patients included in the STILs analysis and those not revealed the 
two groups differed significantly with respect to race with a greater percentage of white 
patients included in the STILs analysis (81% in the cohort not included and 88% in the 
cohort included, p = 0.0001). The two groups did not differ significantly on other baseline 
variables (eTable1). In the parent study (N = 2027; total number of events = 352) the HR 
comparing the RFS of arm C to arm A was 0.51 (95% CI: 0.41 to 0.64, p < 0.0001; 240 
events in 1081 patients for Arm A; 112 events in 946 patients for Arm C). The HR for RFS 
in the cohort of patients in this study was similar with HR = 0.55 (95% CI: 0.40 to 0.77; p = 
0.0003).
STILs data
A comparison was made of the STILs evaluations between the two independent pathologists 
(SB, HB). There was good concordance of the STILs assessment by deciles with 55% 
agreement and a weighted Kappa statistic of 0.66 (95% CI: 0.57 to 0.74). The concordance 
of the dichotomous variable of LPBC status (LPBC if STILs ≥ 60%) classification between 
the two pathologists was excellent with 98% agreement (Kappa = 0.85, 95% CI: 0.64 to 
1.00). The analysis only used the STILs data from the pathologist (H.B.) who reviewed all 
the specimens.
The distribution of STILs overall and by study arm is presented in Table 1. A majority of the 
samples were classified as having between 0 to 19% STILs. There were 94 samples (9.9%) 
that were classified as LPBC and this was balanced between the arms: 48/489 (9.8%) in 
Arm A and 46/456 (10.1%) in Arm C (p = 0.89).
Characteristics associated with lymphocyte predominant breast cancer
Women with LPBC breast cancer (approximately 10% of all patients) were less likely to 
have hormone receptor positive (ER+ or PR+ or both) disease compared to women with 
non-LPBC breast cancer, 31% compared to 57%, respectively (p-value < 0.0001, Table 2). 
In addition, women with LPBC disease were more likely to have breast conserving surgery 
(47% versus 38%), to have poor tumor grade (80% versus 70%), and were more likely to be 
stage N0 (21% versus 13%) although these differences did not achieve statistical 
significance. There were no other differences in baseline characteristics between the two 
groups. Importantly, the two groups were balanced with respect to treatment arm 
assignment.
Recurrence-free survival and STILs
There were 162 disease recurrence events: 8 events in the LPBC group and 154 in the non-
LPBC group. Patients without recurrent disease were followed for a median of 6.9 years 
(min = 0.0 years, max =13.6 years). There was a significant interaction between treatment 
arm and LPBC status (p = 0.026). In particular, patients with LPBC tumors did not appear to 
derive any additional benefit from the addition of trastuzumab (HR = 2.43, 95% CI: 0.58 to 
10.22; p = 0.22). This is in contrast to patients with non-LPBC tumors who appeared to 
derive benefit from the addition of trastuzumab (HR = 0.49, 95% CI: 0.35 to 0.69; p-value < 
0.0001) to chemotherapy. Figure 2 contains the Kaplan-Meier curves comparing the RFS by 
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treatment group for each patient group. In Arm A, the 10-year Kaplan-Meier estimates for 
patients with LPBC tumors and patients with non-LPBC tumors are 90.9% and 64.3%, 
respectively (p=0.004). The corresponding Kaplan-Meier estimates of 10 year RFS for the 
two groups were 80.0% and 79.6%, respectively, for patients in Arm C (p=0.79). We 
performed an exploratory analysis of the ≥50% cut-point and the results are the same. There 
was limited power in the analysis of LPBC status due to the fact that there are only 8 
recurrence events in the LPBC set. Exploratory splitting of the LPBC group into HR-
positive and HR-negative groups results in even less power. The number of patients and 
number of events for the four different groups as defined by LPBC status and HR status are: 
LPBC and HR-positive: N=29, events=0; LPBC and HR-negative: N=65, events=8; Non-
LPBC and HR-positive: N=482, events=84; Non-LPBC and HR-negative: N=369, 
events=70. In the LPBC and HR-positive group, there are no recurrence events out of 29 
patients. This means that in the model it is not possible to get an estimate for the HR-
positive in this group (eTable2). However, the relationship in this group appears to be 
similar to that in the HR-negative group (i.e. both hazard ratios are below 1).
When we adjusted the Cox model for important prognostic variables (age, nodal status, HR 
status, tumor grade, and tumor size), the interaction term for treatment arm and LPBC status 
remained significant (p = 0.04) and so we performed separate multivariable analysis for each 
arm (Table 3; eFigure1). LPBC status was significantly associated with RFS in Arm A (HR 
= 0.19; 95% CI: 0.06 to 0.61, p-value =0.005) but not in Arm C (HR = 1.01; 95% CI: 0.39 to 
2.60; p-value = 0.98). Hormone receptor status was associated with RFS in Arm A (HR = 
0.63; 95% CI: 0.42 to 0.94; p-value = 0.02) but not in Arm C (HR = 0.75; 95% CI: 0.43 to 
1.32; p-value = 0.32).
When we performed the analysis treated the STILs decile levels as a continuous variable, the 
relationships observed above did not change. In particular STILs as deciles was associated 
with RFS in the multivariable model for Arm A (p=0.0002), was not associated with RFS in 
the multivariable model for Arm C (p=0.84), and the arm by STIL decile interaction was 
significant (p=0.0082) (eFigure2).
DISCUSSION
In this prospectively defined, retrospective study, we report that STILs assessed 
dichotomously (LPBC; ≥60% STILs) were significantly associated with outcome in HER2 
positive patients treated with chemotherapy alone, i.e., patients with LPBC had a better 
prognosis following treatment with AC→T without trastuzumab. This association was not 
observed following treatment with AC→T + trastuzumab. Notably, we did not confirm that 
increased STILs, either assessed in deciles or dichotomously (LPBC; ≥60% STILs) were 
predictive of increased benefit from adjuvant trastuzumab. To the contrary, in exploratory 
analyses from this landmark adjuvant trastuzumab trial, we showed that patients with high 
STILs (LPBC; ≥60% STILs) did not benefit from the addition of trastuzumab. However, it 
should be noted that only 94 patients were classified as LPBC and there was a total of only 
eight disease recurrence events. This means that this study was likely underpowered to 
detect a treatment effect in this group. On the other hand, the interaction p-value was 
significant, which indicates that the trastuzumab treatment effect does appear to differ by 
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LPBC status; at the very least, the trastuzumab effect in the LPBC patients appears to be less 
than that in the non-LPBC patients.
Previous reports have suggested that increasing STILs, either as a semi-continuous variable 
(deciles) or as a dichotomous variable (LPBC; ≥60% STILs) is prognostic of decreased 
residual risk following chemotherapy in ER negative breast cancer.10,14 We confirmed this 
semi-continuous association between decreasing residual risk as a function of STILs by 
decile in patients treated with adjuvant chemotherapy alone and the interobserver 
concordance was good. Using the dichotomous cutoff of ≥60% STILs, the interobserver 
concordance was excellent, and the previously prognostic association between those with 
LPBC and a decreased residual risk was confirmed in chemotherapy treated patients alone.
These data have implications with respect to cancer pathogenesis and metastasis. STILs 
have been a known prognostic factor for greater than 75 years and we have confirmed this 
finding in patients with HER2 positive breast cancer treated with chemotherapy without 
trastuzumab in the adjuvant setting1. The presence of a tumor-specific immune response 
may stimulate immune surveillance in these antigenic primary cancers for primary tumor 
control, possibly as a function of the composition of the T-cell receptor repertoire of 
STILs.21,22 These STILs data may seem counterintuitive to other data from whole 
transcriptome analyses, which identified a cohort of genes that can be assigned to immune 
function gene ontology terms and which is predictive of long term RFS in trastuzumab-
treated patients.23
Specifically, our model23 was derived from HER2+ samples from a large randomized 
adjuvant trial of chemotherapy ±trastuzumab in which a large number of unselected genes 
were assessed and systematically we excluded any genes that were prognostic following 
chemotherapy. So our model is includes genes that strictly are predictive of trastuzumab 
response. There are also other important differences between our data and those reported by 
others. The recently reported Denkert et al study15 was a neoadjuvant study in which STILs 
were assessed in smaller needle core biopsy H&E tissue sections, the study included triple 
negative breast carcinomas which may have higher levels of STILs, the end-point was 
different, pCR, and the HER2 targeted treatment was different: the inclusion of a TKI in the 
trial may significantly alter the association between the immune system and the tumor15. 
Importantly, with respect to their immune signature, Denkert et al used a selected candidate 
genes list, with little or no information provided on how the genes were selected. If the 
genes were pre-selected on the basis of association with increased lymphocyte infiltration, 
then their reported association is predictable. Finally, some immune function genes may be 
expressed in epithelial cells, and the expression of many immune function genes reflects 
cellular activity, rather than cell number; thus, the relationship between gene expression 
profiles, derived from mixed cell populations, and number of lymphocytes is complex.
How do these results and other studies of STILs impact clinical treatment decisions, in 
particular the adjuvant trastuzumab therapy treatment decision? These results do not confirm 
those of Loi et al.14 Our findings do not show that increased STILs, either assessed in 
deciles or dichotomously (LPBC; ≥60% STILs) were predictive of increased benefit from 
adjuvant trastuzumab; but, that patients with high STILs (LPBC; ≥60% STILs) did not 
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benefit from the addition of trastuzumab. The observed lack of trastuzumab benefit in the 
small population of LPBC patients treated with chemotherapy + trastuzumab is limited by 
the small numbers of patients, limited events and the exploratory nature of the study and 
they should only be considered hypothesis generating and will require further study in the 
other landmark adjuvant trastuzumab trials24,25.
The strengths of this study include: the predefined methods and cutpoints for STILs 
assessment using consensus guidelines, tandem STILs assessment and adjudication of 
challenging cases, low degree of interobserver variability in STILs assessment, and study in 
a landmark adjuvant trastuzumab randomized clinical trial.20 The major limitation of the 
study was that only a subset of the enrolled patients on N9831 were included in this analysis 
although there did not appear to be substantially meaningful difference between patients 
who provided tissue for analysis and had sufficient tissue for analysis than those who did 
not.
This was an exploratory analysis of the association between STILs and RFS from a subset of 
N9831 women with HER2-positive disease treated with chemotherapy alone or treated with 
concurrent chemotherapy and trastuzumab followed by trastuzumab. These results show that 
patients with tumors classified as LPBC had better RFS when treated with chemotherapy 
alone than patients with tumors not classified as having LPBC. Importantly, LPBC status 
was not associated with RFS in patients treated concurrently with chemotherapy and 
trastuzumab. A significant treatment interaction between LPBC status and trastuzumab 
benefit was observed which raises the question whether women with HER2-positive breast 
cancer with LPBC require treatment with trastuzumab; however, this finding, contradictory 
to previously published results, will require further study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cohort Patient Flow
An indication of the patients from the patient study who were included in the STILs 
analysis.
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Figure 2. Recurrence-Free Survival by Treatment Arm for patients stratified by STILs Status
A. RFS by Arm, STIL=LPBC. B. RFS by Arm, STIL=non-LPBC. LPBC: lymphocyte 
predominant breast cancer; Arm A: doxorubicin/cyclophosphamide followed by weekly 
paclitaxel; Arm C: doxorubicin/cyclophosphamide followed by weekly paclitaxel plus 
trastuzumab followed by trastuzumab alone.
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Table 1
Distribution of STIL classification for each arm separately and for entire group
Total
(N=945)
Arm A
(N=489)
Arm C
(N=456) p value
STIL decile, n (%) 0.2899
 0–9% 318 (33.7%) 171 (35.0%) 147 (32.2%)
 10–19% 236 (25.0%) 126 (25.8%) 110 (24.1%)
 20–29% 139 (14.7%)   65 (13.3%)   74 (16.2%)
 30–39% 69 (7.3%) 27 (5.5%) 42 (9.2%)
 40–49% 45 (4.8%) 28 (5.7%) 17 (3.7%)
 50–59% 44 (4.7%) 24 (4.9%) 20 (4.4%)
 60–69% 39 (4.1%) 17 (3.5%) 22 (4.8%)
 70–79% 29 (3.1%) 17 (3.5%) 12 (2.6%)
 80–89% 17 (1.8%) 10 (2.0%)   7 (1.5%)
 90–100%   9 (1.0%) 4 (0.8)   5 (1.1%)
STILs status, n (%) 0.89
 LPBC: ≥ 60% STIL 94 (9.9%) 48 (9.8%)   46 (10.1%)
 Non-LPBC: < 60% STIL 851 (90.1%) 441 (90.2%)) 410 (89.9%)
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Table 2
Comparison of baseline patient and disease characteristics between patients with LP breast cancer and patients 
with non-LPBC breast cancer.
Characteristic LPBC (N=94) Non-LPBC (N=851) Total (N=945) p value
Arm 0.89
 A 48 (51%) 441 (52%) 489 (52%)
 C 46 (49%) 410 (48%) 456 (48%)
Age, years 0.33
 mean (SD) 51.0 (11.0) 49.7 (10.3) 49.8 (10.4)
 median (min, max) 50.0 (28.0, 77.0) 49.0 (23.0, 80.0) 50.0 (23.0, 80.0)
Race, n (%) 0.38
 White 85 (90%) 743 (87%) 828 (88%)
 Other 9 (10%) 108 (13%) 117 (12%)
Menopausal status, n (%) 0.54
 pre-menopausal or <50 47 (50%) 454 (53%) 501 (53%)
 post-menopausal or ≥ 50 47 (50%) 397 (47%) 444 (47%)
Hormone receptor status, n (%) <0.0001
 ER pos and/or PR pos 29 (31%) 482 (57%) 511 (54%)
 ER and PR neg 65 (69%) 369 (43%) 434 (46%)
Breast surgery, n (%) 0.10
 Breast conserving 44 (47%) 324 (38%) 368 (39%)
 Mastectomy 50 (53%) 527 (62%) 577 (61%)
Nodal status, n (%) 0.27
 node positive (1–3+) 30 (32%) 340 (40%) 370 (39%)
 node positive (4–9+) 25 (27%) 217 (25%) 242 (26%)
 node positive (10+) 14 (15%) 120 (14%) 134 (14%)
 positive sentinel node 5 (5%) 64 (8%) 69 (7%)
 Negative sentinel node 11 (12%) 63 (7%) 74 (8%)
 node negative (no pos. nodes) 9 (10%) 47 (6%) 56 (6%)
Predominant tumor hist, n (%) 0.18
 ductal 92 (98%) 805 (95%) 897 (95%)
 other 2 (2%) 45 (5%) 47 (5%)
 missing 0 1 1
Hist tumor grade (Elson), n (%) 0.06
 poor 75 (80%) 590 (70%) 665 (71%)
 well/intermediate 19 (20%) 248 (30%) 267 (29%)
 missing 0 13 13
Pathologic tumor size, n (%) 0.57
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Characteristic LPBC (N=94) Non-LPBC (N=851) Total (N=945) p value
 ≤ 2.0 cm 40 (43%) 324 (38%) 364 (39%)
 2.1–5.0 cm 48 (51%) 451 (53%) 499 (53%)
 >5.0 cm 6 (6%) 76 (9%) 82 (9%)
Tumor stage, n (%) 0.55
 1 40 (43%) 324 (38%) 364 (39%)
 2 48 (51%) 450 (53%) 498 (53%)
 3 6 (6%) 77 (9%) 83 (9%)
N stage, n (%) 0.11
 0 20 (21%) 110 (13%) 130 (14%)
 1 67 (71%) 692 (81%) 759 (80%)
 2 7 (7%) 47 (6%) 54 (6%)
 3 0 (0%) 2 (0%) 2 (0%)
Received hormonal treatment <0.0001
 yes 24 (26%) 462 (55%) 486 (52%)
 no 70 (74%) 384 (45%) 454 (48%)
 missing 0 5 5
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Table 3
Multivariable models for RFS by each arm separately.
Arm A
N = 489
Number of RFS events = 108
Arm C
N = 456
Number of RFS events = 54
Variable HR (95% CI) p-value HR (95% CI) p-value
STILs dichotomous groups
Age, years 0.98 (0.96–1.00) 0.81 1.00 (0.98–1.03) 0.81
Nodal status
 negative 1.00 (reference) <0.0001 1.00 (reference) 0.005
 1–3 positive 0.70 (0.30–1.62) 3.75 (0.50–28.21)
 4–9 positive 1.50 (0.65–3.43) 3.77 (0.48–29.35)
 10+ positive 2.46 (1.06–5.74) 10.04 (1.31–77.05)
HR status
 negative ER and negative PR 1.00 (reference) 0.02 1.00 (reference) 0.32
 ER and/or PR positive 0.63 (0.42–0.94) 0.75 (0.43–1.32)
Tumor grade (Elson/SBR)
 poor 1.00 (reference) 0.38 1.00 (reference) 0.37
 well/intermediate 0.81 (0.51–1.30) 0.74 (0.39–1.42)
Pathology tumor size, cm 1.08 (0.98–1.19) 0.12 1.00 (0.94–1.06) 0.98
STIL status
 non-LPBC 1.00 (reference) 0.005 1.00 (reference) 0.98
 LPBC 0.19 (0.06–0.61) 1.01 (0.39–2.60)
STILs quasi-continuous
Age, years 0.99 (0.97–1.00) 0.13 1.00 (0.98–1.03) 0.82
Nodal status
 negative 1.00 (reference) <0.0001 1.00 (reference) 0.005
 1–3 positive 0.64 (0.28–1.48) 3.79 (0.50–28.44)
 4–9 positive 1.42 (0.62–3.25) 3.78 (0.49–29.46)
 10+ positive 2.33 (1.00–5.42) 10.10 (1.31–77.65)
HR status
 negative ER and negative PR 1.00 (reference) 0.02 1.00 (reference) 0.32
 ER and/or PR positive 0.62 (0.41–0.92) 0.75 (0.43–1.32)
Tumor grade (Elson/SBR)
 poor 1.00 (reference) 0.15 1.00 (reference) 0.38
 well/intermediate 0.70 (0.44–1.13) 0.75 (0.39–1.43)
JAMA Oncol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Perez et al. Page 17
Arm A
N = 489
Number of RFS events = 108
Arm C
N = 456
Number of RFS events = 54
Variable HR (95% CI) p-value HR (95% CI) p-value
Pathology tumor size, cm 1.08 (0.98–1.19) 0.13 1.00 (0.94–1.06) 0.99
STIL
0.79 (0.70–0.89) 0.0002 1.01 (0.89–1.15) 0.85
JAMA Oncol. Author manuscript; available in PMC 2017 January 01.
